Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
复制标题
DOI：
10.1038/s41586-020-2607-z
复制
发表时间：
2020-10
期刊：
影响因子：
64.8
通讯作者：
Barouch DH
中科院分区：
文献类型：
--
作者：
Mercado NB;Zahn R;Wegmann F;Loos C;Chandrashekar A;Yu J;Liu J;Peter L;McMahan K;Tostanoski LH;He X;Martinez DR;Rutten L;Bos R;van Manen D;Vellinga J;Custers J;Langedijk JP;Kwaks T;Bakkers MJG;Zuijdgeest D;Rosendahl Huber SK;Atyeo C;Fischinger S;Burke JS;Feldman J;Hauser BM;Caradonna TM;Bondzie EA;Dagotto G;Gebre MS;Hoffman E;Jacob-Dolan C;Kirilova M;Li Z;Lin Z;Mahrokhian SH;Maxfield LF;Nampanya F;Nityanandam R;Nkolola JP;Patel S;Ventura JD;Verrington K;Wan H;Pessaint L;Van Ry A;Blade K;Strasbaugh A;Cabus M;Brown R;Cook A;Zouantchangadou S;Teow E;Andersen H;Lewis MG;Cai Y;Chen B;Schmidt AG;Reeves RK;Baric RS;Lauffenburger DA;Alter G;Stoffels P;Mammen M;Van Hoof J;Schuitemaker H;Barouch DH
要结束2019年冠状病毒病（COVID-19）大流行，可能需要一种安全有效的严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）疫苗。对于全球部署和大流行控制而言，只需要一次免疫的疫苗将是最佳选择。在这里，我们展示了单剂量表达SARS-CoV-2刺突(S)蛋白的腺病毒血清型26 （Ad26）载体疫苗在非人灵长类动物中的免疫原性和保护效果。用编码S变异体的Ad26载体或假对照免疫52只恒河猴，经鼻内和气管内感染SARS-CoV-2。最佳的Ad26疫苗诱导了稳健的中和抗体反应，并在SARS-CoV-2攻击后的支气管肺泡灌洗和鼻拭子中提供了完全或接近完全的保护。疫苗诱导的中和抗体滴度与保护效果相关，表明保护与免疫相关。这些数据表明，在非人类灵长类动物中，单针疫苗对SARS-CoV-2具有强大的保护作用。针对SARS-CoV-2的最佳Ad26载体疫苗，称为Ad26. cov2。目前正在临床试验中进行评估。
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. 52 rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
影响因子：
17.1
作者：
Abbink P;Larocca RA;Visitsunthorn K;Boyd M;De La Barrera RA;Gromowski GD;Kirilova M;Peterson R;Li Z;Nanayakkara O;Nityanandam R;Mercado NB;Borducchi EN;Chandrashekar A;Jetton D;Mojta S;Gandhi P;LeSuer J;Khatiwada S;Lewis MG;Modjarrad K;Jarman RG;Eckels KH;Thomas SJ;Michael NL;Barouch DH
通讯作者：
Barouch DH
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
168.9
作者：
Chan, Jasper Fuk-Woo;Yuan, Shuofeng;Yuen, Kwok-Yung
通讯作者：
Yuen, Kwok-Yung
影响因子：
5.5
作者：
Alharbi NK;Padron-Regalado E;Thompson CP;Kupke A;Wells D;Sloan MA;Grehan K;Temperton N;Lambe T;Warimwe G;Becker S;Hill AVS;Gilbert SC
通讯作者：
Gilbert SC